When considering medical treatment in Canada, it is now imperative to keep in mind the power and influence that the pharmaceutical industry brings to bear in Canada’s healthcare system at every stage—from research through development and trials, to approval, marketing, and doctors’ recommendations.
The CCCA Conflict of Interest Task Force analyzes conflicts of interest and other similar issues in an ongoing series of articles found here. New articles in this series will be announced in upcoming CCCA newsletters.
It may be surprising to many that the COVID-19 response was largely directed by individuals and corporations with ideological and financial interests independent of public welfare
The Food and Drug Administration (FDA) is to be an independent regulatory body for human and veterinary drugs, biological products, and medical devices in the United States. In recent years, it has developed financial dependence on private funding sources, creating a threat to its ability to maintain regulatory independence.
COVID-19 ushered in dramatic changes to Canadians’ healthcare and patients’ rights. Underlying some of these changes was an unprecedented pervasive effect upon decision making and policy by the pharmaceutical industry.
